Dr. Adnan Mjalli is an internationally recognized entrepreneur in the business of drug discovery and development of new medicines in the pharmaceutical and biotechnology industry.

The work of Dr. Mjalli goes far beyond drug discovery and development. He is the founder of more than 20 other companies in many areas, including education, energy, agriculture, bioremediation, construction, development, real estate, commerce, and finance. These companies focus on science, education, tourism, entertainment, technology, and the advancement of human capital in developing countries.

Dr. Mjalli attended university in Jordan and postgraduate studies in London, England before obtaining his PhD in Medicinal Chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was completed at the University of Rochester with Professor Richard S. Schlessinger. Since then, Dr. Mjalli has held various positions of increasing leadership responsibilities in research and senior executive management at a number of pharmaceutical and biotechnology companies, including Merck & Co., Inc.

During the early stages of his leadership responsibilities, he was successful in raising close to $1 billion dollars in equity and forged major strategic partnerships with several pharmaceutical and biotechnology companies including Merck & Co., Pfizer, Novo Nordisk, Boehringer Ingelheim, Kanabo Pharmaceuticals of Japan, Cephalon (acquired by Teva), and Forest Labs (acquired by Actavis)

Dr. Mjalli has raised, structured, negotiated, and concluded several multibillion-dollar deals with major global pharmaceutical and biotechnology companies.

So far, Dr. Mjalli has authored hundreds of scientific articles, four book chapters, and has been named an inventor on over 700 patents and patent applications.